UBS Affirms 'Buy' Rating for Abbott Laboratories Despite Diagnostic Weakness

UBS reiterated a 'Buy' rating and $148 price target on Abbott Laboratories despite the company's diagnostic segment weakness. The firm is confident in Abbott's robust growth, with its MedTech division recording 12.2% organic growth in Q2, and expects other segments to offset the diagnostic weakness. Abbott is a global healthcare company focused on diagnostics, medical devices, nutrition, and pharmaceuticals, with a commitment to accessibility.

UBS has reiterated its 'Buy' rating and $148 price target on Abbott Laboratories (NYSE: ABT), despite the company's recent weakness in its diagnostic segment. The investment bank remains confident in Abbott's overall growth prospects, citing robust performance in its MedTech division and expecting other segments to offset the diagnostic weakness.

In the second quarter of 2025, Abbott's MedTech division recorded 12.2% organic growth, surpassing the consensus estimate of 11.2%. This growth was driven by strong sales in the company's medical devices and diagnostics divisions. UBS expects this robust growth to continue, with the MedTech pipeline and other segments offsetting the weakness in the diagnostic segment.

Abbott Laboratories is a global healthcare company focused on diagnostics, medical devices, nutrition, and pharmaceuticals. The company is committed to improving health and well-being across all stages of life through innovative solutions and a dedication to accessibility. Despite the recent challenges in the diagnostic segment, UBS remains bullish on the company's long-term prospects.

UBS's confidence in Abbott's growth prospects is reflected in its price target of $148, which represents a 12.8% increase from the current stock price. The investment bank expects Abbott to continue its strong performance in the MedTech division and other segments, driving overall company growth.

Investors should closely monitor Abbott Laboratories' earnings reports and other market developments to stay informed about the company's performance and the broader market trends affecting its stock price. UBS's positive outlook on Abbott Laboratories provides a strong foundation for investors to consider the company as a potential long-term investment.

References:
[1] https://stockanalysis.com/stocks/abt/forecast/
[2] https://www.ainvest.com/chat/share/rbc-capital-gives-abbott-laboratories-a-thumbs-up-sees-stock-go-higher-whats-the-best-time-to-buy-4bed7a/
[3] https://finance.yahoo.com/news/ubs-shrugs-abbott-laboratories-abt-042355779.html